US FDA approves GE HealthCare’s diagnostic drug for the treatment of heart disease
The US Food and Drug Administration has approved a GE HealthCare diagnostic drug for use in the detection of coronary heart disease. Flyrcado, a radioactive diagnostic drug for positron emission tomography (PET) and myocardial perfusion imaging (MPI), will go on sale in some US markets in early 2025, after which it will be expanded.
ПОПУЛЯРНЫЕ ПОСТЫ
Rescuers search for cyclone survivors in devastated Mayotte
Декабрь 17, 2024
“Gilmore Girls” airs for a second season on Hulu
Декабрь 17, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ
